AZRX Insider Trading Activity and SEC Form 4 Filings
AZRX insider trading summary
No open-market insider purchases or sales of AzurRx BioPharma, Inc. (AZRX) have been reported on SEC Form 4 in the past 12 months.
Latest AZRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 31, 2018 | Edmund Burke Ross Jr. | Insider | Buy | $27K (23,848 @ $1.12) |
| Dec 28, 2018 | Johan M. Spoor | President and CEO | Buy | $50K (38,583 @ $1.30) |
| Dec 28, 2018 | Maged Shenouda | Chief Financial Officer | Buy | $26K (20,000 @ $1.31) |
| Dec 28, 2018 | Charles J Casamento | Insider | Buy | $13K (9,000 @ $1.41) |
| Dec 28, 2018 | Edmund Burke Ross Jr. | Insider | Buy | $35K (29,575 @ $1.18) |
| Dec 27, 2018 | Edmund Burke Ross Jr. | Insider | Buy | $51K (42,922 @ $1.18) |
| Dec 27, 2018 | Edmund Burke Ross Jr. | Insider | Buy | $26K (23,200 @ $1.13) |
| May 2, 2018 | Edmund Burke Ross Jr. | Insider | Buy | $50K (20,000 @ $2.50) |
| Jun 30, 2017 | Pelican Partners LLC | Insider | Sell | $300K (100,000 @ $3.00) |
| Jun 30, 2017 | Matthew Balk | 10% Owner | Sell | $300K (100,000 @ $3.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.